Opinion Piece Outlines 5 Steps To Help Identify, Treat Patients With MDR-TB

Scientific American: Five Interventions for Treating Multidrug-Resistant TB
Ifeanyi Nsofor, medical doctor, CEO of EpiAFRIC, and director of policy and advocacy at Nigeria Health Watch

“…The U.S. Food and Drug Administration has approved an oral combination for the treatment of multidrug-resistant tuberculosis (MDR-TB). … This novel drug combination could be a game changer in managing tuberculosis and lead to increased survival of individuals infected with TB. … It could take a while for the new FDA-approved drug combination to be widely available, especially in resource-poor settings. In the meantime, governments working with communities, health workers, the private sector, and civil society organizations should intensify efforts to prevent tuberculosis, increase adherence to currently available treatments, and deploy appropriate technologies in tuberculosis programming…” (10/2).

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.